ABCSG-Veröffentlichung im renommierten Journal 'Molecular Oncology'

Prestigious Journal ‘Molecular Oncology’ Publishes on ctDNA Sequencing in Breast Cancer


We are thrilled to announce the publication of our latest research in the prestigious journal Molecular Oncology! The study entitled “Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression” represents a significant advancement in breast cancer research.

Key Highlights

Liquid biopsy, particularly ctDNA analysis, is revolutionizing cancer care by enabling early detection, monitoring metastasis, and guiding mutation-targeted therapies. It provides real-time insights into tumor dynamics, facilitating personalized treatment and improving patients’ quality of life. Routine applications such as PIK3CA and ESR1 mutation testing demonstrate the transformative impact of this non-invasive approach.

Download PDF

ABCSG President Prof. Michael Gnant highlights Austria’s leadership in this field: “Austria continues to be at the forefront of breast cancer research, and this publication underscores our commitment to advancing science and improving patient outcomes.

Prof. Gabriel Rinnerthaler, mentor of young researcher Dr. Eva Valentina Klocker, first author of the paper from the Medical University of Graz, highlights the opportunities for young researchers within the ABCSG: “As a young researcher, the ABCSG provides an incredible platform to contribute to groundbreaking work and publish impactful papers.

Prof. Marija Balic, former Head of the Research Unit FE Translational Breast Cancer Research at the Medical University of Graz and now Co-Director of the Magee Womens Cancer Program at the University of Pittsburgh School of Medicine and Director of Translational Research at NSABP, reflects on the collaborative spirit: “This publication is a testament to the strong international collaborations and relentless pursuit of excellence in translational research.

We are extremely proud of the dedication and hard work of our team as they continue to push the boundaries of cancer research and treatment.

Mol Oncol, 2024 Jun 12. doi: 10.1002/1878-0261.13671. Online ahead of print.


Share on